Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion

Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment phase and subsequent safety follow-ups have concluded, with data cleaning and analysis now underway and topline results expected around the end of Q2 2026. This positions BIA 28-6156 as a potential first-in-class disease-modifying therapy aimed at the underlying cause of GBA-PD rather than symptom management alone.

Robust Enrollment Strengthens GBA-PD Research Momentum

The study achieved robust enrollment of 273 genetically confirmed GBA-PD patients across 85 clinical sites in 11 countries in Europe and North America within approximately 18 months, accompanied by notably high patient retention rates. These operational outcomes reflect sustained engagement from participants, families, investigators, and site teams, as highlighted in presentations at the 3rd International GBA1 Meeting 2026 and the ongoing 7th World Parkinson Congress. Such retention metrics lend credibility to the trial’s execution and support the reliability of forthcoming efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics data.

Targeted Trial Design for Genetically Confirmed Patients

The ACTIVATE study employed a randomized, double-blind design to assess BIA 28-6156, a once-daily oral small molecule that functions as an allosteric activator of beta-glucocerebrosidase (GCase). By enhancing GCase activity, the compound seeks to restore sphingolipid recycling, thereby directly addressing the mechanistic defect linked to GBA1 mutations, which represent the largest genetic risk factor for PD and affect 5–15% of patients. The trial’s focus on this genetically defined subgroup, who typically experience earlier symptom onset and faster progression than those with idiopathic PD, provides a targeted framework for evaluating disease modification in a population with pronounced unmet need.

Economic Implications of Emerging GBA-PD Therapy Development

Findings from the ACTIVATE study could inform Health Economics and Outcomes Research (HEOR) evaluations by clarifying whether early intervention with a GCase activator alters disease trajectory in GBA-PD, potentially affecting long-term resource utilization, caregiver burden, and value-based pricing considerations. Should topline results demonstrate meaningful modification of underlying pathology, the therapy may influence market access strategies, reimbursement negotiations, and formulary positioning for genetically stratified Parkinson’s treatments. Bial’s concurrent presentations on treatment adherence and non-motor symptom management further contextualize how such a therapy might integrate into broader care pathways, supporting more precise assessments of clinical and economic value in this high-need subpopulation.